Drug/target (study) [reference] | Subjects n | Dosage, duration | Primary outcome | Secondary outcome |
Benralizumab; anti-IL-5R [53] | 82 | 100 mg every 4 weeks (3 doses) then every 8 weeks (5 doses), 56 weeks | ↔ Moderate-to-severe exacerbations | ↑ FEV1 in intervention group ↔ Health status ↓ Blood and sputum eosinophils |
Benralizumab (TERRANOVA); anti-IL-5R (NCT02155660) [54] | 2255 | 10, 30 or 100 mg every 4 weeks (3 doses) then 8 weekly, 48 weeks | ↔ Exacerbations | ↓ Blood eosinophils ↔ FEV1, SGRQ |
Benralizumab (GALATHEA); anti-IL5R (NCT02138916) [54] | 1656 | 30 or 100 mg every 4 weeks (3 doses) then 8 weekly, 48 weeks | ↔ Exacerbations | ↓ Blood eosinophils ↔ FEV1, SGRQ |
Mepolizumab; anti-IL-5 (NCT01463644) [55] | 18 | 750 mg per month, for 6 months | ↓ Sputum eosinophils | ↓ Blood eosinophils ↔ FEV1, CAT, CRQ, exacerbations |
Mepolizumab; anti-IL-5 (METREX) (NCT02105961) [56] | 1070 | 100 mg or 300 mg every 4 weeks, 52 weeks | ↓ Exacerbations in pre-specified (n=462) eosinophilic group | ↑ Time to first exacerbation ↔ FEV1, SGRQ, CAT |
Mepolizumab; anti-IL-5 (METREO) (NCT02105948) [56] | 674 | 100 mg or 300 mg every 4 weeks, 52 weeks | ↔ Exacerbations | ↔ Time to first exacerbation ↔ FEV1, SGRQ, CAT |
Anti-GATA3 [60] | 23 | Inhaled 10 mg SB010 twice daily, 28 days | Feasibility study | ↓ Sputum eosinophils ↔ FEV1, FeNO, symptoms |
IL-R: interleukin-5 receptor; FEV1: forced expiratory volume in 1 s; CAT: COPD Assessment Test; CRQ: Chronic Respiratory Disease Questionnaire; SGRQ: St George's Respiratory Questionnaire; FeNO: exhaled nitric oxide fraction; ↑: increase; ↓: decrease; ↔: no change.